Engineered biomaterials in stem cell-based regenerative medicine

Abstract

Stem cell-based regenerative therapies, which harness the self-renewal and differentiation properties of stem cells, have been in the spotlight due to their widespread applications in treating degenerative, aging, and other, generally intractable diseases. Therapeutically effective hematopoietic stem cells, mesenchymal stem cells, embryonic stem cells, and induced pluripotent stem cells have been used in numerous basic and translational studies with exciting results. However, pre-/post-transplantation issues of poor cell survival and retention, uncontrolled differentiation, and insufficient numbers of cells engrafted into host tissues are the major challenges in stem cell-based regenerative therapies. Engineered biomaterials have adjustable biochemical and biophysical properties that significantly affect cell behaviors, such as cell engraftment, survival, migration, and differentiation outcomes, thereby enhancing the engraftment of implanted stem cells and guiding tissue regeneration. Therefore, the combination of stem cell biology with bioengineered materials is a promising strategy to improve the therapeutic outcomes of stem cell-based regenerative therapy. In this review, we summarize the advances in the modulation of behaviors of stem cells via engineered biomaterials. We then present different approaches to harnessing bioengineered materials to enhance the transplantation of stem cells. Finally, we will provide future directions in regenerative therapy using stem cells.

Keywords

stem cells / engineered biomaterials / stem cell-based regenerative therapy / adjustable biophysical and biochemical properties / regenerative medicine

References

[1] Langer R, Vacanti JP. Tissue engineering. Science 1993;260:920–6.

[2] Khademhosseini A, Langer R. A decade of progress in tissue engineering. Nat Protoc 2016;11:1775–81.

[3] Madl CM, Heilshorn SC, Blau HM. Bioengineering strategies to accelerate stem cell therapeutics. Nature 2018;557:335–42.

[4] Martin GR. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc Natl Acad Sci U S A 1981;78:7634–8.

[5] Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998;282:1145–7.

[6] Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663–76.

[7] Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861–72.

[8] Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007;318:1917–20.

[9] Olivier EN, Rybicki AC, Bouhassira EE. Differentiation of human embryonic stem cells into bipotent mesenchymal stem cells. Stem Cells 2006;24:1914–22.

[10] Chilton PM, Rezzoug F, Ratajczak MZ, et al. Hematopoietic stem cells from NOD mice exhibit autonomous behavior and a competitive advantage in allogeneic recipients. Blood 2005;105:2189–97.

[11] Pagano SF, Impagnatiello F, Girelli M, et al. Isolation and characterization of neural stem cells from the adult human olfactory bulb. Stem Cells 2000;18:295–300.

[12] Yamanaka S. Pluripotent stem cell-based cell therapy-promise and challenges. Cell Stem Cell 2020;27:523–31.

[13] Kimbrel EA, Lanza R. Next-generation stem cells—ushering in a new era of cell-based therapies. Nat Rev Drug Discov 2020;19:463–79.

[14] Hirsch T, Rothoeft T, Teig N, et al. Regeneration of the entire human epidermis using transgenic stem cells. Nature 2017;551:327–32.

[15] Schwartz SD, Hubschman JP, Heilwell G, et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet 2012;379:713–20.

[16] Mandai M, Watanabe A, Kurimoto Y, et al. Autologous induced stem-cell-derived retinal cells for macular degeneration. N Engl J Med 2017;376:1038–46.

[17] Mitrousis N, Fokina A, Shoichet MS. Biomaterials for cell transplantation. Nat Rev Mater 2018;3:441–56.

[18] Hussey GS, Dziki JL, Badylak SF. Extracellular matrix-based materials for regenerative medicine. Nat Rev Mater 2018;3:159–73.

[19] Tong Z, Solanki A, Hamilos A, et al. Application of biomaterials to advance induced pluripotent stem cell research and therapy. EMBO J 2015;34:987–1008.

[20] Yasuda SY, Ikeda T, Shahsavarani H, et al. Chemically defined and growth-factor-free culture system for the expansion and derivation of human pluripotent stem cells. Nat Biomed Eng 2018;2:173–82.

[21] Kleinman HK, McGarvey ML, Liotta LA, et al. Isolation and characterization of type IV procollagen, laminin, and heparan sulfate proteoglycan from the EHS sarcoma. Biochemistry 1982;21:6188–93.

[22] Hughes CS, Postovit LM, Lajoie GA. Matrigel: a complex protein mixture required for optimal growth of cell culture. Proteomics 2010;10:1886–90.

[23] Liu Z, Tang M, Zhao J, et al. Looking into the future: toward advanced 3D biomaterials for stem-cell-based regenerative medicine. Adv Mater 2018;30:16.

[24] Caliari SR, Burdick JA. A practical guide to hydrogels for cell culture. Nat Methods 2016;13:405–14.

[25] Lou J, Mooney DJ. Chemical strategies to engineer hydrogels for cell culture. Nat Rev Chem 2022;6:726–44.

[26] Lei Y, Schaffer DV. A fully defined and scalable 3D culture system for human pluripotent stem cell expansion and differentiation. Proc Natl Acad Sci U S A 2013;110:18.

[27] Labouesse C, Tan BX, Agley CC, et al. StemBond hydrogels control the mechanical microenvironment for pluripotent stem cells. Nat Commun 2021;12:6132.

[28] Gilbert PM, Havenstrite KL, Magnusson KE, et al. Substrate elasticity regulates skeletal muscle stem cell self-renewal in culture. Science 2010;329:1078–81.

[29] Cosgrove BD, Gilbert PM, Porpiglia E, et al. Rejuvenation of the muscle stem cell population restores strength to injured aged muscles. Nat Med 2014;20:255–64.

[30] Yang C, Tibbitt MW, Basta L, et al. Mechanical memory and dosing influence stem cell fate. Nat Mater 2014;13:645–52.

[31] Li CX, Talele NP, Boo S, et al. MicroRNA-21 preserves the fibrotic mechanical memory of mesenchymal stem cells. Nat Mater 2017;16:379–89.

[32] Madl CM, LeSavage BL, Dewi RE, et al. Maintenance of neural progenitor cell stemness in 3D hydrogels requires matrix remodelling. Nat Mater 2017;16:1233–42.

[33] Gjorevski N, Sachs N, Manfrin A, et al. Designer matrices for intestinal stem cell and organoid culture. Nature 2016;539:560–4.

[34] Kim H, Kumbar SG, Nukavarapu SP. Biomaterial-directed cell behavior for tissue engineering. Curr Opin Biomed Eng 2021;17:25.

[35] Park HJ, Hong H, Thangam R, et al. Static and dynamic biomaterial engineering for cell modulation. Nanomaterials 2022;12:1377.

[36] McMurray RJ, Gadegaard N, Tsimbouri PM, et al. Nanoscale surfaces for the long-term maintenance of mesenchymal stem cell phenotype and multipotency. Nat Mater 2011;10:637–44.

[37] Guvendiren M, Burdick JA. The control of stem cell morphology and differentiation by hydrogel surface wrinkles. Biomaterials 2010;31:6511–8.

[38] Chen W, Villa-Diaz LG, Sun Y, et al. Nanotopography influences adhesion, spreading, and self-renewal of human embryonic stem cells. ACS Nano 2012;6:4094–103.

[39] Almutawaa W, Rohani L, Rancourt DE. Expansion of human induced pluripotent stem cells in stirred suspension bioreactors. Methods Mol Biol 2016;1502:53–61.

[40] Sart S, Agathos SN, Li Y. Engineering stem cell fate with biochemical and biomechanical properties of microcarriers. Biotechnol Prog 2013;29:1354–66.

[41] Zhu F, Yan N, Lu X, et al. Cell reprogramming-inspired dynamically responsive hydrogel boosts the induction of pluripotency via phase-separated biomolecular condensates. Adv Mater 2023;29:202211609.

[42] Weaver VM, Petersen OW, Wang F, et al. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 1997;137:231–45.

[43] Engler AJ, Sen S, Sweeney HL, et al. Matrix elasticity directs stem cell lineage specification. Cell 2006;126:677–89.

[44] Lee J, Abdeen AA, Tang X, et al. Geometric guidance of integrin mediated traction stress during stem cell differentiation. Biomaterials 2015;69:174–83.

[45] Vining KH, Mooney DJ. Mechanical forces direct stem cell behaviour in development and regeneration. Nat Rev Mol Cell Biol 2017;18:728–42.

[46] Chaudhuri O, Gu L, Klumpers D, et al. Hydrogels with tunable stress relaxation regulate stem cell fate and activity. Nat Mater 2016;15:326–34.

[47] Saha K, Keung AJ, Irwin EF, et al. Substrate modulus directs neural stem cell behavior. Biophys J 2008;95:4426–38.

[48] Musah S, Morin SA, Wrighton PJ, et al. Glycosaminoglycan-binding hydrogels enable mechanical control of human pluripotent stem cell self-renewal. ACS Nano 2012;6:10168–77.

[49] Khetan S, Guvendiren M, Legant WR, et al. Degradation-mediated cellular traction directs stem cell fate in covalently crosslinked three-dimensional hydrogels. Nat Mater 2013;12:458–65.

[50] Álvarez Z, Ortega JA, Sato K, et al. Artificial extracellular matrix scaffolds of mobile molecules enhance maturation of human stem cell-derived neurons. Cell Stem Cell 2023;30:219–238.e14.

[51] Nie Y, Zhang K, Zhang S, et al. Nitric oxide releasing hydrogel promotes endothelial differentiation of mouse embryonic stem cells. Acta Biomater 2017;63:190–9.

[52] Lapointe VL, Fernandes AT, Bell NC, et al. Nanoscale topography and chemistry affect embryonic stem cell self-renewal and early differentiation. Adv Healthc Mater 2013;2:1644–50.

[53] Mengqi S, Wen S, Boxin Z, et al. Micro/nano topography with altered nanotube diameter differentially trigger endoplasmic reticulum stress to mediate bone mesenchymal stem cell osteogenic differentiation. Biomed Mater 2020;16:015024.

[54] Chu G, Zhang W, Zhou P, et al. Substrate topography regulates differentiation of annulus fibrosus-derived stem cells via CAV1-YAP-mediated mechanotransduction. ACS Biomater Sci Eng 2021;7:862–71.

[55] Andersson-Rolf A, Zilbauer M, Koo BK, et al. Stem cells in repair of gastrointestinal epithelia. Physiology 2017;32:278–89.

[56] Gonzalez G, Sasamoto Y, Ksander BR, et al. Limbal stem cells: identity, developmental origin, and therapeutic potential. Wiley Interdiscip Rev Dev Biol 2018;7:3.

[57] Fuchs E. Epithelial skin biology: three decades of developmental biology, a hundred questions answered and a thousand new ones to address. Curr Top Dev Biol 2016;116:357–74.

[58] Diehl AM, Chute J. Underlying potential: cellular and molecular determinants of adult liver repair. J Clin Invest 2013;123:1858–60.

[59] Godwin J. The promise of perfect adult tissue repair and regeneration in mammals: Learning from regenerative amphibians and fish. Bioessays 2014;36:861–71.

[60] Hatzimichael E, Tuthill M. Hematopoietic stem cell transplantation. Stem Cells Cloning 2010;3:105–17.

[61] Marquardt LM, Heilshorn SC. Design of injectable materials to improve stem cell transplantation. Curr Stem Cell Rep 2016;2:207–20.

[62] Sortwell CE, Pitzer MR, Collier TJ. Time course of apoptotic cell death within mesencephalic cell suspension grafts: implications for improving grafted dopamine neuron survival. Exp Neurol 2000;165:268–77.

[63] Agashi K, Chau DY, Shakesheff KM. The effect of delivery via narrow- bore needles on mesenchymal cells. Regen Med 2009;4:49–64.

[64] Aguado BA, Mulyasasmita W, Su J, et al. Improving viability of stem cells during syringe needle flow through the design of hydrogel cell carriers. Tissue Eng Part A 2012;18:806–15.

[65] Amer MH, White LJ, Shakesheff KM. The effect of injection using narrow-bore needles on mammalian cells: administration and formulation considerations for cell therapies. J Pharm Pharmacol 2015;67:640–50.

[66] Amer MH, Rose F, Shakesheff KM, et al. Translational considerations in injectable cell-based therapeutics for neurological applications: concepts, progress and challenges. NPJ Regen Med 2017;2:017–0028.

[67] Payne SL, Anandakumaran PN, Varga BV, et al. In vitro maturation of human iPSC-derived neuroepithelial cells influences transplant survival in the stroke-injured rat brain. Tissue Eng Part A 2018;24:351–60.

[68] Rodell CB, Kaminski AL, Burdick JA. Rational design of network properties in guest-host assembled and shear-thinning hyaluronic acid hydrogels. Biomacromolecules 2013;14:4125–34.

[69] Ballios BG, Cooke MJ, Donaldson L, et al. A hyaluronan-based injectable hydrogel improves the survival and integration of stem cell progeny following transplantation. Stem Cell Rep 2015;4:1031–45.

[70] Wang H, Zhu D, Paul A, et al. Covalently adaptable elastin-like protein-hyaluronic acid (ELP-HA) hybrid hydrogels with secondary thermoresponsive crosslinking for injectable stem cell delivery. Adv Funct Mater 2017;27:19.

[71] Ballios BG, Cooke MJ, van der Kooy D, et al. A hydrogel-based stem cell delivery system to treat retinal degenerative diseases. Biomaterials 2010;31:2555–64.

[72] Führmann T, Tam RY, Ballarin B, et al. Injectable hydrogel promotes early survival of induced pluripotent stem cell-derived oligodendrocytes and attenuates longterm teratoma formation in a spinal cord injury model. Biomaterials 2016;83:23–36.

[73] Roche ET, Hastings CL, Lewin SA, et al. Comparison of biomaterial delivery vehicles for improving acute retention of stem cells in the infarcted heart. Biomaterials 2014;35:6850–8.

[74] Lee AS, Inayathullah M, Lijkwan MA, et al. Prolonged survival of transplanted stem cells after ischaemic injury via the slow release of pro-survival peptides from a collagen matrix. Nat Biomed Eng 2018;2:104–13.

[75] Martin JR, Patil P, Yu F, et al. Enhanced stem cell retention and antioxidative protection with injectable, ROS-degradable PEG hydrogels. Biomaterials 2020;263:120377.

[76] Vachon PH. Integrin signaling, cell survival, and anoikis: distinctions, differences, and differentiation. J Signal Transduct 2011;2011:1–18.

[77] Tate CC, Shear DA, Tate MC, et al. Laminin and fibronectin scaffolds enhance neural stem cell transplantation into the injured brain. J Tissue Eng Regen Med 2009;3:208–17.

[78] Pierschbacher MD, Ruoslahti E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 1984;309:30–3.

[79] Plow EF, Haas TA, Zhang L, et al. Ligand binding to integrins. J Biol Chem 2000;275:21785–8.

[80] Wang C, Liu Y, Fan Y, et al. The use of bioactive peptides to modify materials for bone tissue repair. Regen Biomater 2017;4:191–206.

[81] Hersel U, Dahmen C, Kessler H. RGD modified polymers: biomaterials for stimulated cell adhesion and beyond. Biomaterials 2003;24:4385–415.

[82] Ho SS, Murphy KC, Binder BY, et al. Increased survival and function of mesenchymal stem cell spheroids entrapped in instructive alginate hydrogels. Stem Cells Transl Med 2016;5:773–81.

[83] Mhanna R, Öztürk E, Vallmajo-Martin Q, et al. GFOGER-modified MMP-sensitive polyethylene glycol hydrogels induce chondrogenic differentiation of human mesenchymal stem cells. Tissue Eng Part A 2014;20:1165–74.

[84] Somaa FA, Wang TY, Niclis JC, et al. Peptide-based scaffolds support human cortical progenitor graft integration to reduce atrophy and promote functional repair in a model of stroke. Cell Rep 2017;20:1964–77.

[85] Moshayedi P, Nih LR, Llorente IL, et al. Systematic optimization of an engineered hydrogel allows for selective control of human neural stem cell survival and differentiation after transplantation in the stroke brain. Biomaterials 2016;105:145–55.

[86] Tam RY, Fuehrmann T, Mitrousis N, et al. Regenerative therapies for central nervous system diseases: a biomaterials approach. Neuropsychopharmacology 2014;39:169–88.

[87] Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010;141:1117–34.

[88] James AW, LaChaud G, Shen J, et al. A review of the clinical side effects of bone morphogenetic protein-2. Tissue Eng Part B Rev 2016;22:284–97.

[89] Cahill KS, Chi JH, Day A, et al. Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures. JAMA 2009;302:58–66.

[90] Gaharwar AK, Cross LM, Peak CW, et al. 2D nanoclay for biomedical applications: regenerative medicine, therapeutic delivery, and additive manufacturing. Adv Mater 2019;31:1900332.

[91] Gibbs DM, Black CR, Hulsart-Billstrom G, et al. Bone induction at physiological doses of BMP through localization by clay nanoparticle gels. Biomaterials 2016;99:16–23.

[92] Yuan X, Smith RJ Jr., Guan H, et al. Hybrid biomaterial with conjugated growth factors and mesenchymal stem cells for ectopic bone formation. Tissue Eng Part A 2016;22:928–39.

[93] Ferguson EL, Naseer S, Powell LC, et al. Controlled release of dextrin- conjugated growth factors to support growth and differentiation of neural stem cells. Stem Cell Res 2018;33:69–78.

[94] Zhang B, Su Y, Zhou J, et al. Toward a better regeneration through implant-mediated immunomodulation: harnessing the immune responses. Adv Sci 2021;8:2100446.

[95] Kharbikar BN, Mohindra P, Desai TA. Biomaterials to enhance stem cell transplantation. Cell Stem Cell 2022;29:692–721.

[96] Sadtler K, Estrellas K, Allen BW, et al. Developing a pro-regenerative biomaterial scaffold microenvironment requires T helper 2 cells. Science 2016;352:366–70.

[97] Li Y, Chen X, Jin R, et al. Injectable hydrogel with MSNs/microRNA-21-5p delivery enables both immunomodification and enhanced angiogenesis for myocardial infarction therapy in pigs. Sci Adv 2021;7:eabd6740.

[98] Sadtler K, Singh A, Wolf MT, et al. Design, clinical translation and immunological response of biomaterials in regenerative medicine. Nat Rev Mater 2016;1:16040.

[99] Tuinstra HM, Aviles MO, Shin S, et al. Multifunctional, multichannel bridges that deliver neurotrophin encoding lentivirus for regeneration following spinal cord injury. Biomaterials 2012;33:1618–26.

[100] Vegas AJ, Veiseh O, Gürtler M, et al. Long-term glycemic control using polymer-encapsulated human stem cell-derived beta cells in immune-competent mice. Nat Med 2016;22:306–11.

[101] Mohammadi MR, Rodriguez SM, Luong JC, et al. Exosome loaded immunomodulatory biomaterials alleviate local immune response in immunocompetent diabetic mice post islet xenotransplantation. Commun Biol 2021;4:021–02229.

[102] Gaharwar AK, Singh I, Khademhosseini A. Engineered biomaterials for in situ tissue regeneration. Nat Rev Mater 2020;5:686–705.

[103] Safina I, Embree MC. Biomaterials for recruiting and activating endogenous stem cells in situ tissue regeneration. Acta Biomater 2022;143:26–38.

[104] Cipitria A, Boettcher K, Schoenhals S, et al. In-situ tissue regeneration through SDF-1α driven cell recruitment and stiffness-mediated bone regeneration in a critical-sized segmental femoral defect. Acta Biomater 2017;60:50–63.

[105] Xu Z, Wang W, Ren Y, et al. Regeneration of cortical tissue from brain injury by implantation of defined molecular gradient of semaphorin 3A. Biomaterials 2018;157:125–35.

[106] Wang C, Lin K, Chang J, et al. Osteogenesis and angiogenesis induced by porous β-CaSiO(3)/PDLGA composite scaffold via activation of AMPK/ERK1/2 and PI3K/Akt pathways. Biomaterials 2013;34:64–77.

[107] Le LV, Mohindra P, Fang Q, et al. Injectable hyaluronic acid based microrods provide local micromechanical and biochemical cues to attenuate cardiac fibrosis after myocardial infarction. Biomaterials 2018;169:11–21.

[108] Hulsart-Billström G, Yuen PK, Marsell R, et al. Bisphosphonate-linked hyaluronic acid hydrogel sequesters and enzymatically releases active bone morphogenetic protein-2 for induction of osteogenic differentiation. Biomacromolecules 2013;14:3055–63.

[109] Darnell M, Young S, Gu L, et al. Substrate stress-relaxation regulates scaffold remodeling and bone formation in vivo. Adv Healthc Mater 2017;6:1601185.

[110] Srivastava D, DeWitt N. In vivo cellular reprogramming: the next generation. Cell 2016;166:1386–96.

[111] Wapinski OL, Vierbuchen T, Qu K, et al. Hierarchical mechanisms for direct reprogramming of fibroblasts to neurons. Cell 2013;155:621–35.

[112] Gascón S, Murenu E, Masserdotti G, et al. Identification and successful negotiation of a metabolic checkpoint in direct neuronal reprogramming. Cell Stem Cell 2016;18:396–409.

[113] Treutlein B, Lee QY, Camp JG, et al. Dissecting direct reprogramming from fibroblast to neuron using single-cell RNA-seq. Nature 2016;534:391–5.

[114] Zhou Y, Wang L, Vaseghi HR, et al. Bmi1 is a key epigenetic barrier to direct cardiac reprogramming. Cell Stem Cell 2016;18:382–95.

[115] Lu Y, Brommer B, Tian X, et al. Reprogramming to recover youthful epigenetic information and restore vision. Nature 2020;588:124–9.

[116] Wang J, Li Y, Nie G. Multifunctional biomolecule nanostructures for cancer therapy. Nat Rev Mater 2021;6:766–83.

[117] Biswas A, Liu Y, Liu T, et al. Polyethylene glycol-based protein nanocapsules for functional delivery of a differentiation transcription factor. Biomaterials 2012;33:5459–67.

[118] Lee K, Rafi M, Wang X, et al. In vivo delivery of transcription factors with multifunctional oligonucleotides. Nat Mater 2015;14:701–6.

[119] Raftery RM, Gonzalez Vazquez AG, Chen G, et al. Activation of the SOX-5, SOX-6, and SOX-9 trio of transcription factors using a gene-activated scaffold stimulates mesenchymal stromal cell chondrogenesis and inhibits endochondral ossification. Adv Healthc Mater 2020;9:24.

[120] Nguyen LH, Gao M, Lin J, et al. Three-dimensional aligned nanofibers-hydrogel scaffold for controlled non-viral drug/gene delivery to direct axon regeneration in spinal cord injury treatment. Sci Rep 2017;7:42212 .

[121] Warren L, Lin C. mRNA-based genetic reprogramming. Mol Ther 2019;27:729–34.

[122] Devoldere J, Peynshaert K, Dewitte H, et al. Non-viral delivery of chemically modified mRNA to the retina: subretinal versus intravitreal administration. J Control Release 2019;307:315–30.

[123] Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013;339:819–23.

[124] Mali P, Yang L, Esvelt KM, et al. RNA-guided human genome engineering via Cas9. Science 2013;339:823–6.

[125] Lee K, Conboy M, Park HM, et al. Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair. Nat Biomed Eng 2017;1:889–901.

[126] Downing TL, Soto J, Morez C, et al. Biophysical regulation of epigenetic state and cell reprogramming. Nat Mater 2013;12:1154–62.

[127] Zhang C, Wang X, Zhang E, et al. An epigenetic bioactive composite scaffold with well-aligned nanofibers for functional tendon tissue engineering. Acta Biomater 2018;66:141–56.

[128] Sukpaita T, Chirachanchai S, Chanamuangkon T, et al. Novel epigenetic modulation chitosan-based scaffold as a promising bone regenerative material. Cells 2022;11:3217.

[129] Yin X, Mead BE, Safaee H, et al. Engineering stem cell organoids. Cell Stem Cell 2016;18:25–38.

[130] Shanks N, Greek R, Greek J. Are animal models predictive for humans? Philos Ethics Humanit Med 2009;4:1747–5341.

[131] Bartosh TJ, Ylöstalo JH, Mohammadipoor A, et al. Aggregation of human mesenchymal stromal cells (MSCs) into 3D spheroids enhances their antiinflammatory properties. Proc Natl Acad Sci U S A 2010;107:13724–9.

[132] Vinci M, Gowan S, Boxall F, et al. Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biol 2012;10:1741–7007.

[133] Gähwiler BH, Capogna M, Debanne D, et al. Organotypic slice cultures: a technique has come of age. Trends Neurosci 1997;20:471–7.

[134] Sato T, Vries RG, Snippert HJ, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 2009;459:262–5.

[135] Lancaster MA, Knoblich JA. Organogenesis in a dish: modeling development and disease using organoid technologies. Science 2014;345:17.

[136] Clevers H. Modeling development and disease with organoids. Cell 2016;165:1586–97.

[137] Li M, Izpisua Belmonte JC. Organoids—preclinical models of human disease. N Engl J Med 2019;380:569–79.

[138] He J, Zhang X, Xia X, et al. Organoid technology for tissue engineering. J Mol Cell Biol 2020;12:569–79.

[139] Fatehullah A, Tan SH, Barker N. Organoids as an in vitro model of human development and disease. Nat Cell Biol 2016;18:246–54.

[140] Lancaster MA, Corsini NS, Wolfinger S, et al. Guided self-organization and cortical plate formation in human brain organoids. Nat Biotechnol 2017;35:659–66.

[141] Rossi G, Manfrin A, Lutolf MP. Progress and potential in organoid research. Nat Rev Genet 2018;19:671–87.

[142] Rheinwald JG, Green H. Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. Cell 1975;6:331–43.

[143] Pastrana E. Stem cells: the developing human brain—modeled in a dish. Nat Methods 2013;10:929.

[144] Lancaster MA, Renner M, Martin CA, et al. Cerebral organoids model human brain development and microcephaly. Nature 2013;501:373–9.

[145] Barkauskas CE, Chung MI, Fioret B, et al. Lung organoids: current uses and future promise. Development 2017;144:986–97.

[146] Bredenoord AL, Clevers H, Knoblich JA. Human tissues in a dish: the research and ethical implications of organoid technology. Science 2017;355:eaaf9414.

[147] Huch M, Knoblich JA, Lutolf MP, et al. The hope and the hype of organoid research. Development 2017;144:938–41.

[148] Takebe T, Enomura M, Yoshizawa E, et al. Vascularized and complex organ buds from diverse tissues via mesenchymal cell-driven condensation. Cell Stem Cell 2015;16:556–65.

[149] Qian X, Song H, Ming GL. Brain organoids: advances, applications and challenges. Development 2019;146:166074.

[150] Gallico GG 3rd, O’Connor NE, Compton CC, et al. Permanent coverage of large burn wounds with autologous cultured human epithelium. N Engl J Med 1984;311:448–51.

[151] Yui S, Nakamura T, Sato T, et al. Functional engraftment of colon epithelium expanded in vitro from a single adult Lgr5⁺ stem cell. Nat Med 2012;18:618–23.

[152] Fordham RP, Yui S, Hannan NR, et al. Transplantation of expanded fetal intestinal progenitors contributes to colon regeneration after injury. Cell Stem Cell 2013;13:734–44.

[153] Finkbeiner SR, Freeman JJ, Wieck MM, et al. Generation of tissue- engineered small intestine using embryonic stem cell-derived human intestinal organoids. Biol Open 2015;4:1462–72.

[154] Nie YZ, Zheng YW, Ogawa M, et al. Human liver organoids generated with single donor-derived multiple cells rescue mice from acute liver failure. Stem Cell Res Ther 2018;9:017–0749.

[155] Sampaziotis F, Justin AW, Tysoe OC, et al. Reconstruction of the mouse extrahepatic biliary tree using primary human extrahepatic cholangiocyte organoids. Nat Med 2017;23:954–63.

[156] Schwank G, Koo BK, Sasselli V, et al. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell 2013;13:653–8.

[157] Dekkers JF, Berkers G, Kruisselbrink E, et al. Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis. Sci Transl Med 2016;8:344ra84.

[158] Hofer M, Lutolf MP. Engineering organoids. Nat Rev Mater 2021;6:402–20.

[159] Volpato V, Smith J, Sandor C, et al. Reproducibility of molecular phenotypes after long-term differentiation to human iPSC-derived neurons: a multi-site omics study. Stem Cell Rep 2018;11:897–911.

[160] Phipson B, Er PX, Combes AN, et al. Evaluation of variability in human kidney organoids. Nat Methods 2019;16:79–87.

[161] Cederquist GY, Asciolla JJ, Tchieu J, et al. Specification of positional identity in forebrain organoids. Nat Biotechnol 2019;37:436–44.

[162] Garreta E, Kamm RD, Chuva de Sousa Lopes SM, et al. Rethinking organoid technology through bioengineering. Nat Mater 2021;20:145–55.

[163] Qian X, Nguyen HN, Song MM, et al. Brain-region-specific organoids using mini-bioreactors for modeling ZIKV exposure. Cell 2016;165:1238–54.

[164] Przepiorski A, Sander V, Tran T, et al. A simple bioreactor-based method to generate kidney organoids from pluripotent stem cells. Stem Cell Rep 2018;11:470–84.

[165] Sabbagh MF, Heng JS, Luo C, et al. Transcriptional and epigenomic landscapes of CNS and non-CNS vascular endothelial cells. Elife 2018;7:36187.

[166] Czerniecki SM, Cruz NM, Harder JL, et al. High-throughput screening enhances kidney organoid differentiation from human pluripotent stem cells and enables automated multidimensional phenotyping. Cell Stem Cell 2018;22:929–940.e4.

[167] Wimmer RA, Leopoldi A, Aichinger M, et al. Human blood vessel organoids as a model of diabetic vasculopathy. Nature 2019;565:505–10.

[168] Mansour AA, Gonçalves JT, Bloyd CW, et al. An in vivo model of functional and vascularized human brain organoids. Nat Biotechnol 2018;36:432–41.

[169] van den Berg CW, Ritsma L, Avramut MC, et al. Renal subcapsular transplantation of PSC-derived kidney organoids induces neo-vasculogenesis and significant glomerular and tubular maturation in vivo. Stem Cell Rep 2018;10:751–65.

[170] Takebe T, Sekine K, Enomura M, et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature 2013;499:481–4.

[171] Takebe T, Sekine K, Kimura M, et al. Massive and reproducible production of liver buds entirely from human pluripotent stem cells. Cell Rep 2017;21:2661–70.

[172] Homan KA, Gupta N, Kroll KT, et al. Flow-enhanced vascularization and maturation of kidney organoids in vitro. Nat Methods 2019;16:255–62.

[173] Cho AN, Jin Y, An Y, et al. Microfluidic device with brain extracellular matrix promotes structural and functional maturation of human brain organoids. Nat Commun 2021;12:021–24775.

[174] Skylar-Scott MA, Uzel SGM, Nam LL, et al. Biomanufacturing of organ-specific tissues with high cellular density and embedded vascular channels. Sci Adv 2019;5:eaaw2459.

[175] Ranga A, Gobaa S, Okawa Y, et al. 3D niche microarrays for systems-level analyses of cell fate. Nat Commun 2014;5:4324.

[176] Shao Y, Taniguchi K, Gurdziel K, et al. Self-organized amniogenesis by human pluripotent stem cells in a biomimetic implantation-like niche. Nat Mater 2017;16:419–25.

[177] Capeling MM, Czerwinski M, Huang S, et al. Nonadhesive alginate hydrogels support growth of pluripotent stem cell-derived intestinal organoids. Stem Cell Rep 2019;12:381–94.

[178] Broguiere N, Isenmann L, Hirt C, et al. Growth of epithelial organoids in a defined hydrogel. Adv Mater 2018;30:1801621.

[179] Cruz-Acuña R, Quirós M, Farkas AE, et al. Synthetic hydrogels for human intestinal organoid generation and colonic wound repair. Nat Cell Biol 2017;19:1326–35.

[180] DiMarco RL, Dewi RE, Bernal G, et al. Protein-engineered scaffolds for in vitro 3D culture of primary adult intestinal organoids. Biomater Sci 2015;3:1376–85.

[181] Zhu J. Bioactive modification of poly(ethylene glycol) hydrogels for tissue engineering. Biomaterials 2010;31:4639–56.

[182] Do AV, Khorsand B, Geary SM, et al. 3D printing of scaffolds for tissue regeneration applications. Adv Healthc Mater 2015;4:1742–62.

[183] Cao D, Ding J. Recent advances in regenerative biomaterials. Regen Biomater 2022;9:rbac098.

[184] Yang G, Chen Q, Wen D, et al. A therapeutic microneedle patch made from hair-derived keratin for promoting hair regrowth. ACS Nano 2019;13:4354–60.

[185] Gaharwar AK, Avery RK, Assmann A, et al. Shear-thinning nanocomposite hydrogels for the treatment of hemorrhage. ACS Nano 2014;8:9833–42.

[186] Loebel C, Rodell CB, Chen MH, et al. Shear-thinning and self-healing hydrogels as injectable therapeutics and for 3D-printing. Nat Protoc 2017;12:1521–41.

[187] Lokhande G, Carrow JK, Thakur T, et al. Nanoengineered injectable hydrogels for wound healing application. Acta Biomater 2018;70:35–47.

[188] Dimatteo R, Darling NJ, Segura T. In situ forming injectable hydrogels for drug delivery and wound repair. Adv Drug Deliv Rev 2018;127:167–84.

[189] Spiller KL, Nassiri S, Witherel CE, et al. Sequential delivery of immunomodulatory cytokines to facilitate the M1-to-M2 transition of macrophages and enhance vascularization of bone scaffolds. Biomaterials 2015;37:194–207.

[190] Li Y, Xiao Y, Liu C. The horizon of materiobiology: a perspective on material-guided cell behaviors and tissue engineering. Chem Rev 2017;117:4376–421.

[191] Carrow JK, Cross LM, Reese RW, et al. Widespread changes in transcriptome profile of human mesenchymal stem cells induced by two-dimensional nanosilicates. Proc Natl Acad Sci U S A 2018;115:E3905–13.

[192] Camp JG, Wollny D, Treutlein B. Single-cell genomics to guide human stem cell and tissue engineering. Nat Methods 2018;15:661–7.

[193] Bosse R, Singhofer-Wowra M, Rosenthal F, et al. Good manufacturing practice production of human stem cells for somatic cell and gene therapy. Stem Cells 1997;1:275–80.

[194] Bosse R, Kulmburg P, von Kalle C, et al. Production of stem-cell transplants according to good manufacturing practice. Ann Hematol 2000;79:469–76.

[195] Sullivan S, Stacey GN, Akazawa C, et al. Quality control guidelines for clinical-grade human induced pluripotent stem cell lines. Regen Med 2018;13:859–66.

[196] Hao J, Ma A, Wang L, et al. General requirements for stem cells. Cell Prolif 2020;53:4.

[197] Hao J, Cao J, Wang L, et al. Requirements for human embryonic stem cells. Cell Prolif 2020;53:19.

[198] Zhang Y, Wei J, Cao J, et al. Requirements for human-induced pluripotent stem cells. Cell Prolif 2022;55:26.

[199] Yuan BZ. Establishing a quality control system for stem cell-based medicinal products in China. Tissue Eng Part A 2015;21:2783–90.

[200] Xie J, Ekpo MD, Xiao J, et al. Principles and protocols for post-cryopreservation quality evaluation of stem cells in novel biomedicine. Front Pharmacol 2022;13:907943.

[201] Baghbaderani BA, Tian X, Neo BH, et al. cGMP-manufactured human induced pluripotent stem cells are available for pre-clinical and clinical applications. Stem Cell Rep 2015;5:647–59.

[202] Skorska A, Müller P, Gaebel R, et al. GMP-conformant on-site manufacturing of a CD133(+) stem cell product for cardiovascular regeneration. Stem Cell Res Ther 2017;8:016–0467.

[203] Yi T, Kim SN, Lee HJ, et al. Manufacture of clinical-grade human clonal mesenchymal stem cell products from single colony forming unit-derived colonies based on the subfractionation culturing method. Tissue Eng Part C Methods 2015;21:1251–62.

[204] Hirose T, Kotoku J, Toki F, et al. Label-free quality control and identification of human keratinocyte stem cells by deep learning-based automated cell tracking. Stem Cells 2021;39: 1091–100.

RIGHTS & PERMISSIONS

2023 The Author(s) 2023. Published by Oxford University Press on behalf of Higher Education Press.